口腔颌面外科

以下为当前的临床试验。

按位置、状态和其他条件筛选该研究列表。

1. Study Of Zanzalintinib In Combination With Immuno-Oncology Agents In Participants With Solid Tumors

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.
   
   In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

以下为当前的临床试验。

按位置、状态和其他条件筛选该研究列表。

1. Study Of Zanzalintinib In Combination With Immuno-Oncology Agents In Participants With Solid Tumors

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.
   
   In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.